Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies
Status:
Unknown status
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This open, single-arm, exploratory study looked at the efficacy and safety of apatinib in
combination with S-1 as second-line treatment of advanced head and neck malignancies.